Insider Trading Activity Clearside Biomedical, Inc. (NASDAQ:CLSD) – Director Bought 1,100 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Clearside Biomedical, Inc. (NASDAQ:CLSD)

Christy L Shaffer , Director of Clearside Biomedical, Inc. (NASDAQ:CLSD) reportedly Bought 1,100 shares of the company’s stock at an average price of 7 for a total transaction amount of $7,700.00 SEC Form

Insider Trading History For Clearside Biomedical, Inc. (NASDAQ:CLSD)

On 6/7/2016 Venture Advisors Iv S Hatteras, Major Shareholder, bought 414,286 with an average share price of $7.00 per share and the total transaction amounting to $2,900,002.00.View SEC Filing

On 6/7/2016 Clay Thorp, Director, sold 138 with an average share price of $7.00 per share and the total transaction amounting to $966.00.View SEC Filing

On 1/19/2017 Venture Advisors Iii Hatteras, Insider, sold 25,301 with an average share price of $8.63 per share and the total transaction amounting to $218,347.63.View SEC Filing

On 1/20/2017 Clay Thorp, Director, sold 68,485 with an average share price of $8.53 per share and the total transaction amounting to $584,177.05.View SEC Filing

On 2/17/2017 Clay Thorp, Director, sold 41,485 with an average share price of $7.60 per share and the total transaction amounting to $315,286.00.View SEC Filing

On 2/22/2017 Clay Thorp, Director, sold 27,000 with an average share price of $7.55 per share and the total transaction amounting to $203,850.00.View SEC Filing

On 3/16/2017 Clay Thorp, Director, sold 68,485 with an average share price of $6.56 per share and the total transaction amounting to $449,261.60.View SEC Filing

Analyst Ratings For Clearside Biomedical, Inc. (NASDAQ:CLSD)
These are 6 Buy Ratings .
The current consensus rating for Clearside Biomedical, Inc. (NASDAQ:CLSD) is Buy (Score: 3.00) with a consensus target price of $20.50 , a potential (196.67% upside)

Analyst Ratings History For Clearside Biomedical, Inc. (NASDAQ:CLSD)

On 10/24/2016 Stifel Nicolaus Boost Price Target of rating Buy with a price target of $13.00 to $23.00
On 2/24/2017 J P Morgan Chase & Co Initiated Coverage of rating Overweight to Overweight with a price target of $19.00
On 3/14/2017 Needham & Company LLC Lower Price Target of rating Buy with a price target of $18.00
On 4/20/2017 Wedbush Reiterated Rating Outperform with a price target of $27.00
On 5/25/2017 JMP Securities Initiated Coverage of rating Mkt Outperform to Outperform with a price target of $21.00
On 8/7/2017 Cowen and Company Reiterated Rating Buy

Recent Trading Activity for Clearside Biomedical, Inc. (NASDAQ:CLSD)
Shares of Clearside Biomedical, Inc. closed the previous trading session at 6.94 up +0.03 0.43% with 147,236 shares trading hands.